Imspex welcome David to their board of directors. His wealth of experience and strategic vision will greatly contribute to Imspex’s growth and ambition to become a global leader in the delivery of testing solutions at Point-of-Need.

About David Wilson

David Wilson has held pivotal leadership roles in the diagnostics industry, including over a decade at Genzyme Corporation, where he led international sales, marketing, and business development, driving the global success of its Diagnostics Products division. He joined Molecular Detection, spearheading commercialisation of an innovative molecular diagnostics platform targeting antibiotic-resistant bacteria. David’s experience extends to supporting early-stage companies in the diagnostics sector through his work at Alacrita, the life sciences consulting firm. Most recently, as Chief Commercial Officer at Avacta Group Plc., he has shaped the international commercial strategy for its cutting-edge immunodiagnostics portfolio and led the strategic and operational development of a fully integrated diagnostics products business within the Group, most recently via a M&A buy and build strategy. David served on the Executive Committee of the British In Vitro Diagnostics Association (BIVDA). He holds an MBA and BSc (Hons) in Biochemistry and Microbiology.

About Imspex

Imspex is a recognised leader in delivering innovative solutions to clinical and industry testing needs using its advanced GC-MS technology. Imspex’s achievements include leading development of non-invasive breath testing, Breathomics, and receiving the first CE clinical regulatory approval for our COVID-19 breath test in 2022. In 2023, Imspex pioneered the US and European industrial standards for siloxane testing, partnering with the National Physics Laboratory. With a focus on delivering practical and effective solutions to a range of industries’ testing needs, Imspex will use its own and complementary technologies to service the requirement of our partners and customers. With Imspex’s focus on providing fast, accurate, non-invasive solutions, they use cost-effective diagnostic analytics’-based tools enabling healthcare professionals to deliver better patient outcomes.

Imspex recently completed its strategic corporate and operational restructuring, reinstating their status as an SME and enabling them to continue with their innovative diagnostics pathway. Imspex can now reopen engagement with clinical and industry partners to deliver innovative technology with AI solutions. Imspex can now access crucial UK research and development incentives while enhancing their agility in the diagnostic market. Partnering with individual and industry leaders will enable Imspex to accelerate its commercial growth and meet the increasing global demand for innovative diagnostic solutions.